Phosphodiesterase inhibitors in clinical urology

References

• Antoni FA. Molecular diversity of cyclic AMP signalling. Front. Neuroendocrinol. 21(2), 103–132 (2000).
   PubMed Web of Science ®Google Scholar
• Lucas KA, Pitari GM, Kazerounian S et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 52(3), 375–414 (2000).
   PubMed Web of Science ®Google Scholar
• Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ. Res. 93(4), 280–291 (2003).
   PubMed Web of Science ®Google Scholar
• Conti M, Jin SL. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 63, 1–38 (1999).
   PubMed Web of Science ®Google Scholar
• Essayan DM. Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108(5), 671–680 (2001).
   PubMed Web of Science ®Google Scholar
• Maurice DH, Palmer D, Tilley DG et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol. 64(3), 533–546 (2003).
   PubMed Web of Science ®Google Scholar
• Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem. Biophys. Res. Commun. 246(3), 570–577 (1998).
   PubMed Web of Science ®Google Scholar
• Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 273(25), 15559–15564 (1998).
   PubMed Web of Science ®Google Scholar
• Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, Florio VA. Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene 234(1), 109–117 (1999).
   PubMed Web of Science ®Google Scholar
• Fawcett L, Baxendale R, Stacey P et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc. Natl Acad. Sci. USA 97(7), 3702–3707 (2000).
   PubMed Web of Science ®Google Scholar
• Taher A, Meyer M, Stief CG, Jonas U, Forssmann WG. Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J. Urol. 15(1), 32–35 (1997).
   PubMed Web of Science ®Google Scholar
• Holmquist F, Stief CG, Jonas U, Andersson KE. Effects of the nitric oxide synthase inhibitor NG-nitro-l-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol. Scand. 143(3), 299–304 (1991).
   PubMedGoogle Scholar
• Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med. 326(2), 90–94 (1992).
   PubMed Web of Science ®Google Scholar
• Truss MC, Becker AJ, Djamilian MH, Stief CG, Jonas U. Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. Urology 44(4), 553–556 (1994).
   PubMed Web of Science ®Google Scholar
• Kalsi JS, Kell PD. Update on oral treatments for male erectile dysfunction. J. Eur. Acad. Dermatol. Venereol. 18(3), 267–274 (2004).
   PubMed Web of Science ®Google Scholar
• Eardley I, Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int. J. Clin. Pract. 56(4), 300–304 (2002).
   PubMed Web of Science ®Google Scholar
• Gebekor E, Bethell S, Fawcett L. Selectivity of sildenafil and other phosphodiesterase type 5 inhibitors against all human phosphodiesterase families. Eur. Urol. 1(Suppl. 1), Abstract 63 (2001).
   Google Scholar
• Wrishko R, Sorsaburu S, Wong D, Strawbridge A, McGill J. Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. J. Sex. Med. 6(7), 2039–2048 (2009).
   PubMed Web of Science ®Google Scholar
• Küthe A, Mägert H, Uckert S, Forssmann WG, Stief CG, Jonas U. Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. Eur. Urol. 38(1), 108–114 (2000).
   PubMed Web of Science ®Google Scholar
• Heinig R, Weimann B, Dietrich H, Böttcher MF. Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials. Clin. Drug Investig. 31(1), 27–41 (2011).
   PubMed Web of Science ®Google Scholar
• Lowe G, Costabile RA. 10-year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. J. Sex. Med. 9(1), 265–270 (2012).
   PubMed Web of Science ®Google Scholar
• Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J. Sex. Med. 3(1), 28–36; discussion 36 (2006).
   PubMed Web of Science ®Google Scholar
• Gutierrez P, Hernandez P, Mas M. Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. Int. J. Impot. Res. 17(4), 354–358 (2005).
   PubMedGoogle Scholar
• Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur. Urol. 50(5), 940–947 (2006).
   PubMed Web of Science ®Google Scholar
• Gur S, Sikka SC, Hellstrom WJ. Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opin. Investig. Drugs 17(6), 855–864 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao C, Kim SW, Yang DY et al. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. BJU Int. 110(11), 1801–1806 (2012).
   PubMed Web of Science ®Google Scholar
• Goldstein I, McCullough AR, Jones LA et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J. Sex. Med. 9(4), 1122–1133 (2012).
   PubMed Web of Science ®Google Scholar
• Segal R, Burnett AL. Avanafil for the treatment of erectile dysfunction. Drugs Today 48(1), 7–15 (2012).
   PubMedGoogle Scholar
• Paick JS, Ahn TY, Choi HK et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J. Sex. Med. 5(11), 2672–2680 (2008).
   PubMed Web of Science ®Google Scholar
• Kim BH, Yi S, Kim J et al. Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. Clin. Ther. 31(6), 1234–1243 (2009).
   PubMed Web of Science ®Google Scholar
• Paick JS, Kim JJ, Kim SC et al. Efficacy and safety of mirodenafil in men taking antihypertensive medications. J. Sex. Med. 7(9), 3143–3152 (2010).
   PubMed Web of Science ®Google Scholar
• Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, Antunes E, De Nucci G. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur. J. Pharmacol. 591(1–3), 189–195 (2008).
   PubMed Web of Science ®Google Scholar
• Glina S, Toscano I, Gomatzky C et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a Phase II clinical trial. J. Sex. Med. 6(2), 553–557 (2009).
   PubMed Web of Science ®Google Scholar
• Zhao C, Kim SW, Yang DY et al. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur. Urol. 60(2), 380–387 (2011).
   PubMed Web of Science ®Google Scholar
• Park HJ, Park JK, Park K, Min K, Park NC. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. J. Sex. Med. 7(6), 2209–2216 (2010).
   PubMed Web of Science ®Google Scholar
• Kang KK, Yu JY, Yoo M, Kwon JW. The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction. Int. J. Impot. Res. 17(5), 409–416 (2005).
   PubMed Web of Science ®Google Scholar
• Sadeghi-Nejad H, Watson R. Premature ejaculation: current medical treatment and new directions (CME). J. Sex. Med. 5(5), 1037–1050; quiz 1051 (2008).
   PubMed Web of Science ®Google Scholar
• Giuliano F, Clément P. Serotonin and premature ejaculation: from physiology to patient management. Eur. Urol. 50(3), 454–466 (2006).
   PubMedGoogle Scholar
• Athanasios Z, Polyanthi P, George K. The efficacy of duloxetine in the treatment of premature ejaculation. Int. Urol. Nephrol. 39(1), 115–118 (2007).
   PubMed Web of Science ®Google Scholar
• Uckert S, Stanarius A, Stief CG, Wolf G, Jonas U, Machtens S. Immunocytochemical distribution of nitric oxide synthase in the human seminal vesicle: a light and electron microscopical study. Urol. Res. 31(4), 262–266 (2003).
   PubMedGoogle Scholar
• Machtens S, Ckert S, Stief CG, Tsikas D, Frlich Jr, Jonas U. Effects of various nitric oxide-donating drugs on adrenergic tension of human seminal vesicles in vitro. Urology 61(2), 479–483 (2003).
   PubMedGoogle Scholar
• Uckert S, Bazrafshan S, Sonnenberg JE, Kuczyk MA. Effects of phosphodiesterase inhibitors on the contractile responses of isolated human seminal vesicle tissue to adrenergic stimulation. J. Sex. Med. 6(2), 408–414 (2009).
   PubMed Web of Science ®Google Scholar
• Ückert S, Waldkirch ES, Sonnenberg JE, Sandner P, Kuczyk MA, Hedlund P. Expression and distribution of phosphodiesterase isoenzymes in the human seminal vesicles. J. Sex. Med. 8(11), 3058–3065 (2011).
   PubMedGoogle Scholar
• Porst H. An overview of pharmacotherapy in premature ejaculation. J. Sex. Med. 8(Suppl. 4), 335–341 (2011).
   PubMedGoogle Scholar
• Gökçe A, Halis F, Demirtas A, Ekmekcioglu O. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study. BJU Int. 107(8), 1274–1277 (2011).
   PubMed Web of Science ®Google Scholar
• Mattos RM, Marmo Lucon A, Srougi M. Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol. Int. 80(2), 162–165 (2008).
   PubMed Web of Science ®Google Scholar
• Burton TD, Liday C. The comparison of combination SSRI and PDE-5 inhibitor therapy to SSRI monotherapy in men with premature ejaculation. Ann. Pharmacother. 45(7–8), 1000–1004 (2011).
   PubMedGoogle Scholar
• Beach EW. Peyronie’s disease or fibrous cavernositis: some observations. Cal. West. Med. 55(1), 7–10 (1941).
   PubMedGoogle Scholar
• Smith JF, Brant WO, Fradet V et al. Penile sonographic and clinical characteristics in men with Peyronie’s disease. J. Sex. Med. 6(10), 2858–2867 (2009).
   PubMedGoogle Scholar
• Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie’s disease with PDE5 inhibitors: an antifibrotic strategy. Nat. Rev. Urol. 7(4), 215–221 (2010).
   PubMed Web of Science ®Google Scholar
• Ückert S, Mayer M, Stief CG et al. Cavernous blood flow regulates the level of transforming growth factor β1 (TGF β1) in the human corpus cavernosum. Abstract 104. Presented at: 8th Congress of the European Society for Sexual Medicine. Copenhagen, Denmark, 4–7 December 2005.
   Google Scholar
• Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. l-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide 9(4), 229–244 (2003).
   PubMed Web of Science ®Google Scholar
• Bella AJ, Sener A, Foell K, Brock GB. Nonpalpable scarring of the penile septum as a cause of erectile dysfunction: an atypical form of Peyronie’s disease. J. Sex. Med. 4(1), 226–230 (2007).
   PubMed Web of Science ®Google Scholar
• Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J. Sex. Med. 8(5), 1472–1477 (2011).
   PubMed Web of Science ®Google Scholar
• Agrawal V, Ellins E, Donald A, Minhas S, Halcox J, Ralph DJ. Systemic vascular endothelial dysfunction in Peyronie’s disease. J. Sex. Med. 5(11), 2688–2693 (2008).
   PubMedGoogle Scholar
• Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. Urol. Clin. North Am. 22(2), 247–261 (1995).
   PubMedGoogle Scholar
• Jacobsen SJ, Guess HA, Panser L et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch. Fam. Med. 2(7), 729–735 (1993).
   PubMedGoogle Scholar
• Hieble JP, Ruffolo RR Jr. The use of α-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol. Res. 33(3), 145–160 (1996).
   PubMed Web of Science ®Google Scholar
• Tarter TH, Vaughan ED Jr. Inhibitors of 5α-reductase in the treatment of benign prostatic hyperplasia. Curr. Pharm. Des. 12(7), 775–783 (2006).
   PubMed Web of Science ®Google Scholar
• McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J. Urol. 177(3), 1071–1077 (2007).
   PubMed Web of Science ®Google Scholar
• Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur. Urol. 53(6), 1236–1244 (2008).
   PubMed Web of Science ®Google Scholar
• Porst H, Kim ED, Casabé AR et al.; LVHJ Study Team. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur. Urol. 60(5), 1105–1113 (2011).
   PubMed Web of Science ®Google Scholar
• Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an α-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int. J. Impot. Res. 21(2), 122–128 (2009).
   PubMed Web of Science ®Google Scholar
• Tamimi NA, Mincik I, Haughie S, Lamb J, Crossland A, Ellis P. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int. 106(5), 674–680 (2010).
   PubMed Web of Science ®Google Scholar
• Güler C, Tüzel E, Dogantekin E, Kiziltepe G. Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement? Urol. Int. 80(2), 181–185 (2008).
   PubMed Web of Science ®Google Scholar
• Guven EO, Balbay MD, Mete K, Serefoglu EC. Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. Int. Urol. Nephrol. 41(2), 287–292 (2009).
   PubMed Web of Science ®Google Scholar
• Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur. Urol. 61(5), 917–925 (2012).
   PubMed Web of Science ®Google Scholar
• Drasa K, Bara P. Tadalafil and changes in bladder outlet obstruction index in men with benign prostatic hyperplasia. Eur. Urol. Suppl. 11(4), Abstract 118 (2012).
   Google Scholar
• Zhao C, Kim SH, Lee SW et al. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 107(12), 1943–1947 (2011).
   PubMedGoogle Scholar
• Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur. Urol. 51(6), 1717–1723 (2007).
   PubMed Web of Science ®Google Scholar
• Liguori G, Trombetta C, De Giorgi G et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J. Sex. Med. 6(2), 544–552 (2009).
   PubMed Web of Science ®Google Scholar
• Bechara A, Romano S, Casabé A et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J. Sex. Med. 5(9), 2170–2178 (2008).
   PubMed Web of Science ®Google Scholar
• Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J. Urol. 28(1), 17–22 (2010).
   PubMed Web of Science ®Google Scholar
• Gacci M, Vittori G, Tosi N et al. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Sex. Med. 9(6), 1624–1633 (2012).
   PubMed Web of Science ®Google Scholar
• Andersson KE, Chapple C, Wein A. The basis for drug treatment of the overactive bladder. World J. Urol. 19(5), 294–298 (2001).
   PubMedGoogle Scholar
• Truss MC, Uckert S, Stief CG, Kuczyk M, Jonas U. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization. Urol. Res. 24(3), 123–128 (1996).
   PubMedGoogle Scholar
• Truss MC, Uckert S, Stief CG, Forssmann WG, Jonas U. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol. Res. 24(3), 129–134 (1996).
   PubMedGoogle Scholar
• Ückert S, Sandner P, Sigl K et al. Is there a role of the phosphodiesterase type 5 (PDE5) in the control of detrusor smooth muscle? A functional and molecular biology study. J. Urol. 181(4 Suppl.), Abstract 152 (2009).
   Google Scholar
• Truss MC, Stief CG, Uckert S et al. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J. Urol. 19(5), 344–350 (2001).
   PubMed Web of Science ®Google Scholar
• Kaiho Y, Nishiguchi J, Kwon DD et al. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction. BJU Int. 101(5), 615–620 (2008).
   PubMed Web of Science ®Google Scholar
• Gacci M, Del Popolo G, Macchiarella A et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J. Urol. 178(5), 2040–2043; discussion 2044 (2007).
   PubMedGoogle Scholar
• Giuliano FA, Lamb J, Crossland A, Haughie S, Ellis P, Tamimi NA. A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder. BJU Int. 106(5), 666–673 (2010).
   PubMed Web of Science ®Google Scholar
• Smet PJ, Edyvane KA, Jonavicius J, Marshall VR. Colocalization of nitric oxide synthase with vasoactive intestinal peptide, neuropeptide Y, and tyrosine hydroxylase in nerves supplying the human ureter. J. Urol. 152(4), 1292–1296 (1994).
   PubMedGoogle Scholar
• Stief CG, Uckert S, Truss MC, Becker AJ, Machtens S, Jonas U. A possible role for nitric oxide in the regulation of human ureteral smooth muscle tone in vitro. Urol. Res. 24(6), 333–337 (1996).
   PubMedGoogle Scholar
• Taher A, Schulz-Knappe P, Meyer M et al. Characterization of cyclic nucleotide phosphodiesterase isoenzymes in the human ureter and their functional role in vitro. World J. Urol. 12(5), 286–291 (1994).
   PubMed Web of Science ®Google Scholar
• Stief CG, Taher A, Truss M et al. Phosphodiesterase isoenzymes in human ureteral smooth muscle: identification, characterization, and functional effects of various phosphodiesterase inhibitors in vitro. Urol. Int. 55(4), 183–189 (1995).
   PubMedGoogle Scholar
• Kühn R, Uckert S, Stief CG et al. Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide-dependent pathways. Urol. Res. 28(2), 110–115 (2000).
   PubMedGoogle Scholar
• Gratzke C, Uckert S, Kedia G et al. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol. Res. 35(1), 49–54 (2007).
   PubMedGoogle Scholar
• Becker AJ, Stief CG, Meyer M, Truss MC, Forssmann WG, Jonas U. The effect of the specific phosphodiesterase-IV-inhibitor rolipram on the ureteral peristalsis of the rabbit in vitro and in vivo. J. Urol. 160(3 Pt 1), 920–925 (1998).
   PubMed Web of Science ®Google Scholar
• Katevuo K, Kanto J, Kleimola T. Aminophylline in ureterolithiasis: preliminary report. Int. J. Clin. Pharmacol. Ther. Toxicol. 19(11), 512–513 (1981).
   PubMedGoogle Scholar